Vozmozhnosti primeneniya blokatorov retseptorov angiotenzina II pri metabolicheskom sindrome i arterial'noy gipertenzii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Angiotensin II receptor blockers are considered as one of the three major classes of antihypertensive drugs in the treatment of arterial hypertension in patients with metabolic syndrome. Each representative of this group (losartan, valsartan, candesartan, irbesartan, telmisartan) has clinical and pharmacological features and nuances of clinical applications. Based on their analysis, the algorithm of differential selection of a specific drug is presented.

Full Text

Restricted Access

References

  1. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013;31: 1281-357.
  2. Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2010;369:201-07.
  3. Недогода С.В., Барыкина И.Н., Брель У.А., Чаляби Т.А., Мазина Г.В., Подольская Е.В., Ледяева А.А. Возможности телмизартана в ангио- и кардиопротекции и улучшении показателей углеводного обмена при нарушении толерантности к глюкозе // Системные гипертензии 2009. № 2. С. 47-51.
  4. Vitale С, Mercuro G, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6-11.
  5. Лебедева М.В., Стахова Т.Ю., Минакова Е.Г., Зайцева Л.И., Северова М.М., Пулин А.А. Функция эндотелия у больных с артериальной гипертензией и нарушением обмена мочевой кислоты // Вестник РАМН 2010. № 12. С. 44-6.
  6. КобалаваЖ.Д., КотовскаяЮ.В., Толкачева В.В., Мальто А.С. Мочевая кислота - ключевой компонент кардиоренометаболического континуума // Кардиоваскулярная терапия и профилактика 2008. № 4. С. 95-106.
  7. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20(3):369-79.
  8. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;366:1477-90.
  9. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003;2:29-34.
  10. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58(3):177-80.
  11. Lindholm LH, Persson M, Alaupovic P, Carlberg B. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003;21(8):1563-74.
  12. Мамирбаева К.М., Мычка В.Б., СергиенкоВ.Б., Чазова И.Е. Метаболический синдром и антагонисты рецепторов ангиотензина II // Кардиоваскулярная терапия и профилактика 2007. № 2. С. 42-51.
  13. Kintscher U, Bramlage P, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007;6:12-6.
  14. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43(5):993-1002.
  15. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013; 7(3):229-35.
  16. Derosa G, Fogari D, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32:261-68.
  17. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, openlabel, prospectivestudy. Clin Ther 2010;32: 492-505.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies